Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy

Nature Medicine

Volumn 9, Issue 6, 2003, Pages 768-773

  Katsuno, Masahisa ^a   Adachi, Hiroaki ^a   Doyu, Manabu ^a   Minamiyama, Makoto ^a   Sang, Chen ^a   Kobayashi, Yasushi ^a   Inukai, Akira ^a   Sobue, Gen ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; FLUTAMIDE; GONADORELIN AGONIST; LEUPRORELIN; POLYGLUTAMINE; TESTOSTERONE;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CASTRATION; CELL NUCLEUS; CELL TRANSPORT; CONTROLLED STUDY; DRUG EFFECT; DRUG RECEPTOR BINDING; HISTOPATHOLOGY; KENNEDY DISEASE; MALE; MOTOR DYSFUNCTION; MOTOR NEURON DISEASE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SEX DIFFERENCE; TESTIS; TESTOSTERONE BLOOD LEVEL; TESTOSTERONE RELEASE; TRANSGENIC MOUSE;

ANDROGEN ANTAGONISTS; ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; FLUTAMIDE; HUMANS; LEUPROLIDE; MALE; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; MUSCLE, SKELETAL; MUSCULAR DISORDERS, ATROPHIC; ORGAN SIZE; PEPTIDES; PHENOTYPE; RECEPTORS, ANDROGEN; SPINAL CORD; TESTOSTERONE;

ANIMALIA; MUS MUSCULUS;

EID: 0038714285     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm878     Document Type: Article

References (39)

1. Kennedy, W.R., Alter, M. & Sung, J.H. Progressive proximal spinal and bulbar muscular atrophy of late onset. A sex-linked recessive trait. Neurology 18, 671-680 (1968).
2. Sobue, G. et al. X-linked recessive bulbospinal neuronopathy. A clinicopathological study. Brain 112, 209-232 (1989).
3. Sobue, G. et al. Subclinical phenotypic expressions in heterozygous females of X-linked recessive bulbospinal neuronopathy. J. Neurol. Sci. 117, 74-78 (1993).
4. Mariotti, C. et al. Phenotypic manifestations associated with CAG-repeat expansion in the androgen receptor gene in male patients and heterozygous females: a clinical and molecular study of 30 families. Neuromuscul. Disord. 10, 391-397 (2000).
5. Schmidt, B.J., Greenberg, C.R., Allingham-Hawkins, D.J. & Spriggsm E.L. Expression of X-linked bulbospinal muscular atrophy (Kennedy disease) in two homozygous women. Neurology 59, 770-772 (2002).
6. La Spada, A.R., Wilson, E.M., Lubahn, D.B., Harding, A.E. & Fischbeck, K.H. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352, 77-79 (1991).
7. Tanaka, F. et al. Founder effect in spinal and bulbar muscular atrophy (SBMA). Hum. Mol. Genet. 5, 1253-1257 (1996).
8. Doyu, M. et al. Severity of X-linked recessive bulbospinal neuronopathy correlates with size of the tandem CAG repeat in androgen receptor gene. Ann. Neurol. 32, 707-710 (1992).
9. Igarashi, S. et al. Strong correlation between the number of CAG repeats in androgen receptor genes and the clinical onset of features of spinal and bulbar muscular atrophy. Neurology 42, 2300-2302 (1992).
10. Zoghbi, H.Y. & Orr, H.T. Glutamine repeats and neurodegeneration. Annu. Rev. Neurosci. 23, 217-247 (2000).
11. Li, M. et al. Nuclear inclusions of the androgen receptor protein in spinal and bulbar muscular atrophy. Ann. Neurol. 44, 249-254 (1998).
12. Li, M. et al. Nonneural nuclear inclusions of androgen receptor protein in spinal and bulbar muscular atrophy. Am. J. Pathol. 153, 695-701 (1998).
13. Ross, C.A. Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders. Neuron 35, 819-822 (2002).
14. Taylor, J.P. & Fischbeck, K.H. Altered acetylation in polyglutamine disease: an opportunity for therapeutic intervention? Trends Mol. Med. 8, 195-197 (2002).
15. Katsuno, M. et al. Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron 35, 843-854 (2002).
16. Huggins, C. & Hodges, C.V. Studies on prostatic cancer. I. The effects of castration, of estrogen and of androgen injection on serum phosphates in metastatic carcinoma of the prostate. Cancer Res. 1, 293-297 (1941).
17. Labrie, F. Mechanism of action and pure antiandrogenic properties of flutamide. Cancer 72 (suppl. 12), 3816-3827 (1993).
18. Yamamoto, A., Lucas, J.J. & Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 101, 57-66 (2000).
19. Kemppainen, J.A. & Wilson, E.M. Agonist and antagonist activities of hydroxyflutamide and casodex relate to androgen receptor stabilization. Urology 48, 157-163 (1996).
20. Lu, S., Simon, N.G., Wang, Y. & Hu, S. Neural androgen receptor regulation: effects of androgen and antiandrogen. J. Neurobiol. 41, 505-512 (1999).
21. Tomura, A. et al. The subnuclear three-dimensional image analysis of androgen receptor fused to green fluorescence protein. J. Biol. Chem. 276, 28395-28401 (2001).
22. Walcott, J.L. & Merry, D.E. Ligand promotes intranuclear inclusions in a novel cell model of spinal and bulbar muscular atrophy. J. Biol. Chem. 277, 50855-50859 (2002).
23. Takeyama, K. et al. Androgen-dependent neurodegeneration by polyglutamine-expanded human androgen receptor in Drosophila. Neuron 35, 855-864 (2002).
24. Fischbeck, K.H., Lieberman, A., Bailey, C.K., Abel, A. & Merry, D.E. Androgen receptor mutation in Kennedy's disease. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 354, 1075-1078 (1999).
25. Lieberman, A.P., Harmison, G., Strand, A.D., Olson, J.M. & Fischbeck, K.H. Altered transcriptional regulation in cells expressing the expanded polyglutamine androgen receptor. Hum. Mol Genet. 11, 1967-1976 (2002).
26. Gottlieb, B. Pinsky, L., Beitel, L.K. & Trifiro, M. Androgen insensitivity. Am. J. Med. Genet. 89, 210-217 (1999).
27. MacLean, H.E., Warne, G.L. & Zajac, J.D. Defects of androgen receptor function: from sex reversal to motor neurone disease. Mol. Cell. Endocrinol. 112, 133-141 (1995).
28. Kobayashi, Y. et al. Chaperones Hsp70 and Hsp40 suppress aggregate formation and apoptosis in cultured neuronal cells expressing truncated androgen receptor protein with expanded polyglutamine tract. J. Biol. Chem. 275, 8772-8778 (2000).
29. Adachi, H et al. HSP70 chaperone over-expression ameliorates phenotypes of the SBMA transgenic mouse model by reducing nuclear-localized mutant AR protein. J. Neurosci. 23, 2203-2211 (2003).
30. Cummings, C., J. et al. Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1. Nat. Genet. 19, 148-154 (1998).
31. Cummings, C.J. et al. Over-expression of inducible HSP70 chaperone suppresses neuropathology and improves motor function in SCA1 mice. Hum. Mol. Genet. 10, 1511-1518 (2001).
32. McCampbell, A. et al. Histone deacetylase inhibitors reduce polyglutamine toxicity. Proc. Natl. Acad. Sci. USA 98, 15179-15184 (2001).
33. Steffan, J.S. et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413, 739-743 (2001).
34. Hockly, E. et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl. Acad. Sci. USA 100, 2041-2046 (2003).
35. Kobayashi, Y. et al. Caspase-3 cleaves the expanded androgen receptor protein of spinal and bulbar muscular atrophy in a polyglutamine repeat length-dependent manner. Biochem. Biophys. Res. Commun. 252, 145-150 (1998).
36. Niwa, H., Yamamura, K. & Miyazaki, J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108, 193-199 (1991).
37. Adachi, H. et al. Transgenic mice with an expanded CAG repeat controlled by the human AR promoter show polyglutamine nuclear inclusions and neuronal dysfunction without neuronal cell death. Hum. Mol. Genet. 10, 1039-1048 (2001).
38. Luo, S. et al. Daily dosing with flutamide or Casodex exerts maximal antiandrogenic activity. Urology 50, 913-919 (1997).
39. Trottier, Y. et al. Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias. Nature 378, 403-406 (1995).